Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024.
- Revenue
- +8.28%
- EPS
- +36.7%
- Free cash flow
- +19.1%
- Total debt
- +44.9%
Quarter to September 2026, against a year earlier
Follow DHR
Alert me
Danaher Corporation (DHR) P/E ratio
As of 5 November 2026, Danaher Corporation (DHR) trades at a P/E ratio of 37.0×. Over the past ten years it has ranged from 11.6× (February 2016) to 52.6× (September 2024); the current reading is higher than 73% of that period. That is above the Diagnostics & Research industry median of 34.5× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 45.2× | 4.84% |
| FY2024 | 43.1× | 18.31% |
| FY2023 | 36.4× | 53.92% |
| FY2022 | 23.6× | (28.59%) |
| FY2021 | 33.1× | (16.06%) |
| FY2020 | 39.5× | 19.40% |
| FY2019 | 33.0× | 37.22% |
| FY2018 | 24.1× | 5.64% |
| FY2017 | 22.8× | 21.27% |
| FY2016 | 18.8× | 45.43% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 36.2× | 7.38% |
| Jun 2026 | 33.7× | (7.72%) |
| Mar 2026 | 36.5× | (19.09%) |
| Dec 2025 | 45.2× | 11.14% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NTRA Natera, Inc. compare | n/m |
| IQV IQVIA Holdings Inc. compare | 31.8× |
| A Agilent Technologies, Inc. compare | 33.8× |
| ILMN Illumina, Inc. compare | 35.6× |
| TMO Thermo Fisher Scientific Inc. compare | 35.8× |
| DHR Danaher Corporation | 37.0× |
| MTD Mettler-Toledo International, Inc. compare | 37.6× |
| IDXX IDEXX Laboratories, Inc. compare | 44.8× |
| WAT Waters Corporation compare | 194× |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on DHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement